- EndoChoice Holdings (NYSE:GI) priced at 15, the low end of its estimated range. It raised $95 million by offering 6.35 million shares.
- The medical device company makes endoscopic imaging systems with wide field-of-view cameras, devices and infection control products and pathology services for treating a wide range of gastrointestinal conditions, including colon cancer.
- EndoChoice’s revenues have nearly doubled in the past three years, from $34 million in 2012 to $61.4 million in 2014. The company has yet to produce a profit, posting losses of $1.2 million, $25.5 million and $52.7 million for 2012, 2013 and 2014, respectively.
- EndoChoice is led by Mark Gilreath, 49, who founded the company in 2007.
EndoChoice founder and CEO Mark Gilreath.
No comments:
Post a Comment